These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18591547)

  • 1. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
    Oza AM; Eisenhauer EA; Elit L; Cutz JC; Sakurada A; Tsao MS; Hoskins PJ; Biagi J; Ghatage P; Mazurka J; Provencher D; Dore N; Dancey J; Fyles A
    J Clin Oncol; 2008 Sep; 26(26):4319-25. PubMed ID: 18591547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
    Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
    Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
    Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
    Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
    Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
    Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
    J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of erlotinib in patients with advanced biliary cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2006 Jul; 24(19):3069-74. PubMed ID: 16809731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
    Rothenberg ML; LaFleur B; Levy DE; Washington MK; Morgan-Meadows SL; Ramanathan RK; Berlin JD; Benson AB; Coffey RJ
    J Clin Oncol; 2005 Dec; 23(36):9265-74. PubMed ID: 16361624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
    Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
    Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
    Hirte H; Oza A; Swenerton K; Ellard SL; Grimshaw R; Fisher B; Tsao M; Seymour L
    Gynecol Oncol; 2010 Sep; 118(3):308-12. PubMed ID: 20646751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
    Janmaat ML; Gallegos-Ruiz MI; Rodriguez JA; Meijer GA; Vervenne WL; Richel DJ; Van Groeningen C; Giaccone G
    J Clin Oncol; 2006 Apr; 24(10):1612-9. PubMed ID: 16575012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.